FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D C | 20540 |
|----------------|------|-------|
| vvasiliigtoii, | D.C. | 20049 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | |
|---------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average b | ourden | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | <u> </u> | | | , | 2001110 | | | 2 3 . 0 | | | | | | | |
|--|---------|----------------------|------------|---------------------------------------|---|---|--|-------------------------|------------------|--------------------------|---|---|--|--|---|---|---|------------|--|
| 1. Name and Address of Reporting Person* <u>Jones Ryan Alexander</u> | | | | | | 2. Issuer Name and Ticker or Trading Symbol <u>Kyverna Therapeutics, Inc.</u> [KYTX] | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner | | | | |
| (Last) | , | irst) HERAPEUTICS | (Middle) | | | 3. Date of Earliest Transaction (Month/Day/Year) 05/28/2024 | | | | | | | | X Officer (give title Other (specify below) Chief Financial Officer | | | | | |
| 5980 HORTON ST., STE 550 | | | | | 4.1 | f Ame | endme | nt, Date | of Origina | l Filed | I (Month/Da | Lin | Individual or Joint/Group Filing (Check Applicable Line) | | | | | | |
| (Street) EMERY | VILLE C | A | 94608 | | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | | | | | | | | | |
| (City) (State) (Zip) | | | | | | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | |
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | I to | | | | | | | | | |
| | | Tab | le I - No | n-Deri | vativ | e Se | curit | ies Ac | quired | , Dis | posed c | of, or Be | eneficia | ly Owned | I | | | | |
| 1. Title of Security (Instr. 3) 2. Trans: Date (Month/L | | | | | action 2A. Deemed Execution Date, if any (Month/Day/Year) | | | Code (Instr. 5) | | | red (A) or str. 3, 4 and | nd Securities Beneficially Owned Following | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) Price | | Reporte Transac (Instr. 3 | tion(s) | | | (Instr. 4) | |
| Common Stock 05/28 | | | | | 28/202 | 3/2024 | | M ⁽¹⁾ | | 10,87 | 10,870 A | | 3 36,804 | | | D | | | |
| Common Stock 05/28 | | | | 28/202 | 3/2024 | | M ⁽²⁾ | | 7,14 | 6 A \$0. | | 3 43 | 43,950 | | D | | | | |
| | | | Table II - | | | | | | | | osed of converti | | | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) 2. Conversion Date Of Date (Month/Day/Year) 3. Transaction Date Execution Date, if any (Month/Day/Year) | | | | ransaction of code (Instr. Derivative | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4) | | | ties ng e Security | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | ly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | |
| | | | | | Code | v | (A) | (D) | Date Exercisa | | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Stock Option (Right to Buy) | \$0.73 | 05/28/2024 | | | M | | | 10,870 | (1) | | (1) | Common Stock | 10,870 | \$0 | 0 | | D | | |
| Stock Option (Right to | \$0.73 | 05/28/2024 | | | M | | | 7,146 | (2) | | (2) | Common Stock | 7,146 | \$0 | 2,192 | | D | | |

Explanation of Responses:

- 1. 25% of the original number of shares subject to the option vested on April 15, 2021, and 1/48th of the original number of shares subject to the option vested in monthly installments thereafter.
- 2. 25% of the original number of shares subject to the option vested on January 1, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

By: /s/ Ryan Jones 05/29/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.